Filing Flows › Aytu Biopharma (AYTU) › Q2 FY25
Aytu Biopharma (AYTU) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed Feb 12, 2025
Aytu Biopharma (AYTU) reported revenue of $16.2M for the second quarter fiscal 2025 (Q2 FY25), -13% from a year earlier and -2% from the quarter before. Operating margin was -10.4%, net earnings $788K (4.9% of revenue).
Aytu Biopharma, Q2 FY25: revenue $16.2M (-14% year over year), operating margin -10.4%, net earnings $788K, operating cash flow $2.9M. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16.2M | -2% | -13% |
| Operating profit | −$1.7M | — | — |
| Net earnings | $788K | — | — |
| Operating cash flow | $2.9M | — | — |
| Free cash flow | $2.9M | — | — |
What changed
Revenue was $16.2M in Q2 FY25, down 13% year over year and down 2% from the previous quarter.
Gross margin was 66.5%, down 11.4 points from a year earlier. Operating costs exceeded revenue by $1.7M, an operating margin of -10.4%. Operating expenses grew 9% against a revenue fall of 13%. The fastest-growing cost line was Other operating costs (+144%). Net earnings were $788K. The effective tax rate was -56.0%. Non-operating items added $2.2M, 436% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $2.9M, 369% of net earnings. Non-cash charges added back $1.3M of depreciation and amortization and $151K of share-based compensation. Working capital and other items added $674K. Capital expenditures of $6K left free cash flow of $2.9M.
Questions
What was Aytu Biopharma's revenue in the second quarter fiscal 2025?
Aytu Biopharma (AYTU) reported revenue of $16.2M for the second quarter fiscal 2025 (Q2 FY25), -13% from a year earlier and -2% from the quarter before.
Was Aytu Biopharma profitable in the second quarter fiscal 2025?
Operating loss was $1.7M (-10.4% of revenue) and net earnings $788K.
Source: Aytu Biopharma 10-Q on SEC EDGAR.